- Home
- FULC vs SIGA Comparison
FULC vs SIGA Comparison
Compare FULC & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FULC | SIGA |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.1M | 421.8M |
| IPO Year | 2019 | 1997 |
Fundamental Metrics
Financial Performance| Metric | FULC | SIGA |
|---|---|---|
| Price | $14.60 | $6.25 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $15.88 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 387.9K |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 9.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.03 |
| Revenue | N/A | ★ $172,249,641.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | ★ N/A | $6.07 |
| Revenue Growth | ★ 2752.05 | N/A |
| 52 Week Low | $2.32 | $4.95 |
| 52 Week High | $15.74 | $9.62 |
Technical Indicators
Market Signals| Indicator | FULC | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 72.49 | 42.93 |
| Support Level | $8.63 | $6.13 |
| Resistance Level | $15.74 | $6.15 |
| Average True Range (ATR) | 1.23 | 0.22 |
| MACD | 0.26 | 0.12 |
| Stochastic Oscillator | 82.56 | 86.43 |
Price Performance
Historical ComparisonAbout FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.